SCHEMBL974565

SCHEMBL974565

O=c1[nH]c2cc(Cl)c(Cl)cc2cc1P(=O)(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 7/20 0.48
GRIN3B O60391 7/20 0.48
GRIN1 Q05586 7/20 0.48
GRIN2A Q12879 7/20 0.48
GRIN2B Q13224 7/20 0.48
GRIN2C Q14957 7/20 0.48
GRIN3A Q8TCU5 7/20 0.48
GRIA1 P42261 4/20 0.48
GRIA2 P42262 4/20 0.48
GRIA3 P42263 4/20 0.48
GRIA4 P48058 4/20 0.48
LMNA P02545 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
MAPT P10636 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
THPO P40225 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27548155 0.84 KMT2A (0.36) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2844839 0.82 CA12 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL27551438 0.81 GRIN2D (0.34) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7740662 0.81 GRIA1 (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7742754 0.81 PRKAG1 (0.42) GRIK1
SCHEMBL7648730 0.80 GRIN2D (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8828084 0.79 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL8828097 0.79 DAO (0.37) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL7740551 0.79 PRKAG1 (0.43) CYP1A2BLMKMT2AHSD17B10DAO
SCHEMBL6939746 0.79 GRIN2D (0.37) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1060182-B1 NOVEL PRODRUGS FOR PHOSPHORUS-CONTAINING COMPOUNDS METABASIS THERAPEUTICS INC (US) 2012-12-19 EP claimed
EP-1586321-B1 New use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2008-12-10 EP claimed
US-7351399-B2 Prodrugs for phosphorus-containing compounds METABASIS THERAPEUTICS, INC. (US) 2008-04-01 US claimed
US-7247610-B2 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI 2007-07-24 US claimed
US-7101879-B2 Treatments for neurotoxicity in Alzheimer's Disease MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2006-09-05 US claimed
US-20050288240-A1 Novel-prodrugs for phosphorus-containing compounds ERION MARK D 2005-12-29 US claimed
EP-1586321-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2005-10-19 EP claimed
US-20050101597-A1 Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage PHARMACIA CORPORATION 2005-05-12 US claimed
US-20050054619-A1 Use of glutamate antagonists for the treatment of cancer IKONOMIDOU HRISSANTHI (DE) 2005-03-10 US claimed
WO-2005007106-A2 COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE PHARMACIA CORPORATION (US) 2005-01-27 WO claimed
EP-1100504-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS Eisai Co., Ltd. (JP) 2001-05-23 EP claimed
US-6172043-B1 GENETIC ENGINEERED POLYPEPTIDE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2001-01-09 US claimed
EP-1015013-A1 TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY beta-AMYLOID PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-07-05 EP claimed
EP-1002535-A1 New use of glutamate antagonists for the treatment of cancer Ikonomidou, Hrissanthi (DE) 2000-05-24 EP claimed
WO-2000024395-A1 NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER IKONOMIDOU HRISSANTHI (DE) 2000-05-04 WO claimed
WO-2000001376-A2 PHARMACEUTICAL COMPOSITIONS AND THEIR USES FOR TREATMENT OF DEMYELINATING DISORDERS EISAI CO., LTD (JP) 2000-01-13 WO claimed
WO-1998030229-A1 TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 1998-07-16 WO claimed
EP-0640612-B1 Novel derivatives from 2-(1H)-quinolinone, process for their preparation and pharmaceutical compositions containing them ADIR (FR) 1998-04-22 EP claimed
US-5646132-A TREATING CEREBRAL ISCHEMIA ADIR ET COMPAGNIE (FR) 1997-07-08 US claimed
US-5536709-A INHIBITORS OF HYPERACTIVATION OF EXCITATORY AMINO ACIDS ADIR ET COMPAGNIE (FR) 1996-07-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288240-A1 Novel-prodrugs for phosphorus-containing compounds HCRTR2, CYP2R1, SLC22A8 GRIN2D 832/4885GRIN3B 398/4885GRIN1 998/4885
US-20050101597-A1 Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage GRIN1, GRIN2A, GRIN2B GRIN2D 16/4885GRIN3B 5/4885GRIN1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.